Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove ...

Three state legislatures have moved forward with dementia-related legislation that includes mandating biomarker testing coverage by insurance plans, creating new memory care licensure and creating a ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

A Tennessee bill that would require health insurance and TennCare to cover biomarker testing, which gives doctors more ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due to standardization issues. Recommendations include educating clinicians, ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

Lung cancer remains the leading cause of cancer deaths in Virginia, according to a new report from the American Lung Association. The 2025 “State of Lung Cancer” report for Virginia found in most ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

‘I Tried Midi Health for Biomarker Testing—Here’s What I Learned About My Health’ originally appeared on Parade. Considering that I’m a journalist, it’s not a surprise that I believe that knowledge is ...

Waiting for chest X-rays or lab results to diagnose pneumonia and other lung-related diseases may not be necessary in the ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...